OBLITERIDE
YEAR IN REVIEW 2018
CURE CANCER FASTER
A MESSAGE FROM

ANDREA GOMES MORRISON
DIRECTOR, OBLITERIDE

From day one, more than 9,000 Obliteriders, including over 660 new walkers this year, committed to support the Hutch’s research.

Obliteriders came together once again to rally our community behind Fred Hutch’s big and bold goal of curing cancer faster. From day one, more than 9,000 Obliteriders, including more than 660 walkers, committed to support the Hutch’s research. These riders and walkers reached out to their communities and invited more than 60,000 donors to invest in the work that is fueling our search for cures.

This year, we grew the Obliteride family and added our inaugural 5K walk. The walk gave teams the opportunity to include people who had not been able to participate in the past, including children. We also hit two major milestones. We had our largest team to date: Team Amazon, with 133 members. And we saw our largest fundraising team in the history of Obliteride: Team Microsoft & Friends, which raised $180,610.

Our participants each have unique stories and motivations for clipping in and lacing up their riding and walking shoes. One rider didn’t know how to ride a bike, but she learned in six weeks and completed the 25-mile route to honor her dad. Another rider took Obliteride global and completed a virtual, 24-hour ride in Madrid. And a 30-year-old breast cancer patient undergoing treatment completed the 5K walk because cancer at her age — at any age — is not OK. These are just three out of thousands of Obliteriders audaciously declaring that we need to end cancer once and for all.

Fred Hutch can rally and grow this passionate community thanks to our sponsors, and we are forever grateful. Join us in 2019, when our impact will be even bigger!

ANDREA GOMES MORRISON
Cure cancer faster. It is not just a tagline for Obliteride. It is what drives and inspires us every day. Fred Hutch’s history is one of pioneering groundbreaking treatments — from bone marrow transplantation more than 40 years ago to today’s exciting advances in personalized medicine and treatments that harness the body’s immune system to fight cancer. Hutch scientists are at the forefront of a sea change that will transform the way cancer is treated, with the goal of developing curative therapies for cancers by 2025.

What also drives and inspires us is the passion and commitment from our Obliteride family — now six years strong. The generosity of our Obliteride sponsors makes it possible for us to direct 100 percent of all rider- and walker-raised funds to fuel groundbreaking research in labs all across campus. These funds are vital to our work on cancer cures and have supported a variety of innovative research projects, including studies for brain, breast, lung, ovarian, and prostate cancers.

We are extremely fortunate to be part of a community that is willing to step up and join forces with us to face this incredible challenge.

Together, we will make a difference. Together, we will cure cancer faster.

Thank you.

GARY GILLILAND, M.D., Ph.D.
Obliteride unites people around a common mission and is fueled by a common passion — to CURE CANCER FASTER. We rally in support of others — family, friends, or colleagues — or to celebrate or commemorate a personal experience with the disease. Obliteride is about getting involved and making a difference.

The first five years were all about the RIDE. Since Obliteride began, we’ve built a community of over 8,400 riders who have ridden over 490,000 miles and raised in excess of $14 million to support cancer research at Fred Hutch.

This year, we created a whole new way to Obliteride with the introduction of our new 5K WALK. The walk took Obliteride “beyond the bike” as we welcomed over 660 walkers into the Obliteride family. It was wonderful to see participants of all ages — from teen years [and younger] to seniors — making strides to cure cancer faster.

And finally, Obliteride would not be possible without the help of our fantastic VOLUNTEER community. This year, over 575 volunteers dedicated more than 3,980 hours volunteering their time not only over Obliteride weekend, but also in the months and weeks leading up to the event. We are forever grateful for their incredible support!
The Honor Wall, sponsored by Seattle Genetics, is a highlight of the event weekend. It provides a unique opportunity for participants to recognize and share who they are riding or walking for with the entire Obliteride community.
**WE ARE OBLITERIDE**

- **Participants on a Team**: 98.9%
- **Walkers**: 662
  - Walkers (Under 18): 108
- **Riders**: 1564
  - First-Time Riders: 746
  - Returning Riders: 818
- **Volunteers**: 578
- **Volunteer Hours**: 3986
- **30 States Represented**
- **International Participants**: 3
- **PaceSetters**: 247
  - People Raised Over $2,000
- **High 5**: 72
  - Raised Over $5,000 or More
- **Survivors (Self-Reported)**: 183
- **Male**: 51%
  - Female: 45%
  - Undisclosed: 4%
Obiteride would not be possible without the generous help of our fantastic volunteer community. To everyone who volunteered in 2018, thank you from the bottom of our soles and spokes!

This year, 282 Fred Hutch and SCCA employees rode and walked in Obiteride and could be recognized by their blue Cure Cancer Faster T-shirt or green Fred Hutch jersey.
## INSPIRATION TO RIDE

<table>
<thead>
<tr>
<th>Reason</th>
<th>100-MILE</th>
<th>50-MILE</th>
<th>25-MILE</th>
<th>WALK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support or honor others</td>
<td>30%</td>
<td>30%</td>
<td>30%</td>
<td>19%</td>
</tr>
<tr>
<td>Support Fred Hutch</td>
<td>70%</td>
<td>37%</td>
<td>7%</td>
<td>10%</td>
</tr>
<tr>
<td>Have fun with friends</td>
<td>7%</td>
<td>37%</td>
<td>30%</td>
<td>19%</td>
</tr>
<tr>
<td>Personal fitness</td>
<td>7%</td>
<td>46%</td>
<td>30%</td>
<td>14%</td>
</tr>
<tr>
<td>Part of a work team</td>
<td>28%</td>
<td>30%</td>
<td>21%</td>
<td>14%</td>
</tr>
<tr>
<td>I’m a survivor</td>
<td>16%</td>
<td>44%</td>
<td>30%</td>
<td>14%</td>
</tr>
<tr>
<td>Do something new</td>
<td>12%</td>
<td>25%</td>
<td>24%</td>
<td>19%</td>
</tr>
<tr>
<td>Someone is making me do it</td>
<td>1%</td>
<td>24%</td>
<td>30%</td>
<td>14%</td>
</tr>
<tr>
<td>Watched in the past</td>
<td>1%</td>
<td>25%</td>
<td>24%</td>
<td>19%</td>
</tr>
</tbody>
</table>

*Respondents selected their top 3 reasons for riding*
TOP OBLITERIDE FUNDRAISERS

Total fundraising
$2.55M

TOP 10 FUNDRAISING INDIVIDUALS

<table>
<thead>
<tr>
<th>NAME</th>
<th>ROUTE</th>
<th>TEAM</th>
<th>DONATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paula Reynolds</td>
<td>50-Mile Rider</td>
<td>CureCyclists</td>
<td>$53,630</td>
</tr>
<tr>
<td>Harvey Kanter</td>
<td>100-Mile Rider</td>
<td>Blue Nile</td>
<td>$53,415</td>
</tr>
<tr>
<td>Richard Kaplan</td>
<td>25-Mile Rider</td>
<td>Microsoft &amp; Friends</td>
<td>$36,831</td>
</tr>
<tr>
<td>Julie Nordstrom</td>
<td>50-Mile Rider</td>
<td>CureCyclists</td>
<td>$26,020</td>
</tr>
<tr>
<td>Peter Nelson</td>
<td>100-Mile Rider</td>
<td>Team IPCR</td>
<td>$22,905</td>
</tr>
<tr>
<td>Michelle Shleifer</td>
<td>25-Mile Rider</td>
<td>Team Jerry Jaffe</td>
<td>$20,965</td>
</tr>
<tr>
<td>Chad Robins</td>
<td>50-Mile Rider</td>
<td>Adaptive Biotechnologies</td>
<td>$18,870</td>
</tr>
<tr>
<td>Jamie Rawding</td>
<td>50-Mile Rider</td>
<td>CureCyclists</td>
<td>$18,355</td>
</tr>
<tr>
<td>Mark Fleischauer</td>
<td>100-Mile Rider</td>
<td>Team JHKelly</td>
<td>$17,100</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>50-Mile Rider</td>
<td>Washington Holdings</td>
<td>$16,350</td>
</tr>
</tbody>
</table>

Please note: this data was current as of October 1, 2018. Final event totals may differ.

TOP 10 FUNDRAISING TEAMS

<table>
<thead>
<tr>
<th>TEAM</th>
<th>TEAM CAPTAIN</th>
<th>NO. OF PARTICIPANTS</th>
<th>DONATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microsoft &amp; Friends</td>
<td>David Powell</td>
<td>85</td>
<td>$180,610</td>
</tr>
<tr>
<td>CureCyclists</td>
<td>Dave Kolk</td>
<td>36</td>
<td>$153,885</td>
</tr>
<tr>
<td>Blue Nile</td>
<td>Sacha Lyewlutatsing</td>
<td>39</td>
<td>$84,799</td>
</tr>
<tr>
<td>Adaptive Biotechnologies</td>
<td>Christa Poel</td>
<td>83</td>
<td>$82,795</td>
</tr>
<tr>
<td>Village People</td>
<td>Susie Plummer</td>
<td>19</td>
<td>$64,460</td>
</tr>
<tr>
<td>Juno</td>
<td>Patty Grossbard</td>
<td>78</td>
<td>$56,290</td>
</tr>
<tr>
<td>Amazon</td>
<td>Jonathan Malo</td>
<td>133</td>
<td>$54,833</td>
</tr>
<tr>
<td>Team IPCR</td>
<td>Peter Nelson</td>
<td>23</td>
<td>$50,510</td>
</tr>
<tr>
<td>Team JHKelly</td>
<td>Mark Fleischauer</td>
<td>35</td>
<td>$48,793</td>
</tr>
<tr>
<td>Compass Construction</td>
<td>Alan Thesenvitz</td>
<td>33</td>
<td>$48,295</td>
</tr>
</tbody>
</table>

Please note: this data was current as of October 1, 2018. Final event totals may differ.
WHERE THE MONEY GOES

Obliteride funds research in the areas of greatest need at Fred Hutch. From basic sciences and public health to deep exploration into organ-specific cancers and immunotherapy, Obliteride has funded over $14 million in research over the past six years. The areas we’ve been able to support with funds raised from walker and rider donations include:

**LUNG CANCER**
Gaining a deeper understanding of how genetic factors influence lung cancer in smokers and non-smokers to provide a more targeted treatment.

**PROSTATE CANCER**
Fred Hutch investigators recently published research linking BRCA mutations with metastatic prostate cancer, helping us identify those more at risk.

**BRAIN CANCER**
Tumor Paint helps surgeons distinguish between the tumor and the healthy brain cells, allowing for complete and precise removal of the tumor.

**BREAST CANCER**
Fred Hutch researchers are reducing breast cancer incidence and impact by identifying risk factors for the disease, developing new methods of detecting its presence, and helping to predict health outcomes based on a woman’s genetics and other factors.

**OVARIAN CANCER**
Better detection, understanding, and treatment are all critical to increasing survival rates.

**CLINICAL RESEARCH**
Groundbreaking clinical trials are providing patients with new cures.

**ENVIRONMENT**
Does where you live matter? Environmental exposure, lifestyle choices, and access to health care and community services all impact the incidence of cancer.

**INFECTION**
More than 1 in 5 cancers worldwide are caused by infection. Avoid infection, avoid some cancers. HPV vaccination (pioneered here at Fred Hutch) has the potential to eradicate nearly all cervical cancer and many head and neck cancers.

**TUMOR RESEARCH**
Moving lab theory, data models, and tissue typing from the lab to the bedside as rapidly as possible.

**IMMUNOTHERAPY**
Fred Hutch is paving the way with less invasive and less toxic cancer treatments. Accelerating this research is vital to curing cancer faster.

"I’m a physician scientist at Fred Hutch. Multiple myeloma is a cancer that’s currently incurable, and here in my laboratory, we’re focused on curing it. Our research is really devoted to using the immune system as a means of attacking and destroying the cancer. We take a patient’s own immune cells out of their body, change them, and re-educate them, so they become cancer attack dogs. And we put them back into the patient, where they seek out and destroy the disease. Fred Hutch is a leader in immunotherapy. There is no place in the world that I believe will more quickly move science from the laboratory to patients, where we can make a difference. When you support Obliteride, you’re changing lives."

"I’m a researcher in the computational biology program at Fred Hutch and every day I come to work to find better ways to target cancer cells. If you think of a lock and key analogy, we think of the outside of a cancer cell as a lock. If we design the protein that has the right three-dimensional shape, using our models of the biophysics and our math and algorithms, then we can find the key that will fit into that lock and allow us to specifically target and open that cancer cell to treatment. We’re only able to do this work because of generous support from donors like you, so thank you."

"Many people don’t realize that up to 20 percent of cancers are caused by infectious agents. One of those cancers is stomach cancer, which is caused by this bacterium, *Helicobacter pylori*, that we study here in the lab. We’re trying to understand how this works so that we can eliminate stomach cancer. In between NIH grant cycles, Obliteride bridge funding helped us keep our projects going so we could keep the science moving forward. On behalf of my team, I would like to thank everybody involved in Obliteride, the volunteers, the bikers, the walkers, the donors. Thank you for all you do."

"My lab studies the brain of the zebrafish. We study how genes function to control the development of the brain in order to understand their normal functions, so that we can understand what goes wrong when those genes are activated in cancer and hopefully be able to stop them. If we study the normal function of a cancer-associated gene in a zebrafish embryo, we are also studying its normal function in humans and in human cancer. The endeavor of basic science is to understand those normal functions because we won’t be able to understand what goes wrong in cancer unless we understand what the genes are normally supposed to do. Because of Obliteride, we’re able to get these fundamental insights into the functions of genes that are associated with cancer. So on behalf of me and my entire research team, thank you."
LEAD OUT SPONSOR
UNIVERSITY VILLAGE®

FOUNDING SPONSOR
SLOAN FOUNDATION

HOSPITALITY SPONSORS
Blazing Bagels
Brew Dr Kombucha
Chateau St Michelle/MERF/14 Hands
KIND
Pagliacci
Rocky Pond Winery
Talking Rain
Tom Douglas Restaurants

CENTURY SPONSORS
amazon
SAFEWAY
Albertsons
SINEGAL FOUNDATION

CYCLING PARTNERS
Davey Engstrom
Gregg’s Cycle
Joe the Bicycle Fixer
Mobile Bicycle Rescue
Old Town Bicycle
Velo Bike Shop

BREAKAWAY SPONSORS
Costco
K5
The Sahsen Fund
Seattle Genetics

FRIENDS OF OBLITERIDE
Microsoft
NAIOP
Pacific Market International
Pedal Anywhere
tagboard

DYNAMO SPONSORS
AV FACTORY
Bartell Drugs
Beam Suntory
Elysian Brewing
JH Kelly

REST STOP SPONSORS
blue nile
REAM INK
OFC

OBLITERIDE • FRED HUTCH / YEAR IN REVIEW 2018
THANK YOU
2018 OBLITERIDERS

THANK YOU OBLITERIDERS
for coming out strong this year to help put cancer behind us. Your miles and fundraising dollars are giving Fred Hutch researchers the fuel they need to catalyze the next big breakthrough.

We hope you are proud of what we have accomplished together — this bold orange community of ours!

Looking forward to seeing you again for Obliteride 2019: August 9 — 10!

OBLITERIDE.ORG
SAVE THE DATE:
AUGUST 9 – 10, 2019

OBLITERIDE
Fred Hutchinson Cancer Research Center
1100 Fairview Ave N., Mail Stop J5-200
Seattle, WA 98109
206.667.RIDE (7433)

To learn more about Fred Hutch’s research to prevent, diagnose and treat cancer, visit www.fredhutch.org.